[Clinical experience of the use of autologous mononuclear bone marrow cells in patients with ischemic heart disease and dilated cardiomyopathy].
Between March 2003 and February 2005 cell therapy with mononuclear bone marrow cells (MBMC) was used in 38 and 4 patients with ischemic heart disease and dilated cardiomyopathy, respectively. Intracardiac administration of MBMC (87+/-12 millions) was carried out during coronary artery bypass surgery and/or left ventricular aneurysm resection (n=25) or in cardiac catheterization laboratory (n=17). For verification of cells fixation they were labeled with "Ceretec" 99mTc-HMPAO. Accumulation of labeled cells after 24 hours was 1.6+/-0.001%. After 6 months parameters of intracardiac hemodynamics and transitory myocardial perfusion defects improved significantly in all patients with ischemic heart disease.
Akhmedov
Sh D
ShD
Babokin
V E
VE
Riabov
V V
VV
Suslova
T E
TE
Chernov
V I
VI
Sazonova
S I
SI
Rogovskaia
Iu V
IuV
Korkin
Iu G
IuG
Motreva
A P
AP
Shipulin
V M
VM
Karpov
R S
RS
D000328:Adult; D016026:Bone Marrow Transplantation / Q000379:methods*; D002311:Cardiomyopathy, Dilated / Q000503:physiopathology / Q000628:therapy*; D006439:Hemodynamics; D006801:Humans; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000637:transplantation; D017202:Myocardial Ischemia / Q000503:physiopathology / Q000628:therapy*; D019690:Technetium Tc 99m Exametazime / Q000032:analysis; D016896:Treatment Outcome
D019690:Technetium Tc 99m Exametazime